MA31236B1 - Utilisation de chitosane pour augmenter le taux de croissance des ongles - Google Patents

Utilisation de chitosane pour augmenter le taux de croissance des ongles

Info

Publication number
MA31236B1
MA31236B1 MA32200A MA32200A MA31236B1 MA 31236 B1 MA31236 B1 MA 31236B1 MA 32200 A MA32200 A MA 32200A MA 32200 A MA32200 A MA 32200A MA 31236 B1 MA31236 B1 MA 31236B1
Authority
MA
Morocco
Prior art keywords
chitosan
growth rate
nails
nail
nail growth
Prior art date
Application number
MA32200A
Other languages
Arabic (ar)
English (en)
Inventor
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31236(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA31236B1 publication Critical patent/MA31236B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation de chitosane, d'un dérivé de chitosane ou d'un sel physiologiquement acceptable de celui-ci, pour augmenter le taux de croissance des ongles. La présente invention concerne en outre l'utilisation de chitosane pour accélérer le taux de croissance des ongles lors d'un traitement contre une maladie des ongles, une dystrophie des ongles ou d'autres conditions des ongles, afin de raccourcir considérablement les traitements spécifiques desdites maladies des ongles, de ladite dystrophie ou desdites autres conditions des ongles.
MA32200A 2007-02-14 2009-09-04 Utilisation de chitosane pour augmenter le taux de croissance des ongles MA31236B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102335A EP1958638A1 (fr) 2007-02-14 2007-02-14 Utilisation de chitosanes pour augmenter la vitesse de pousse des ongles
PCT/EP2008/051477 WO2008098869A2 (fr) 2007-02-14 2008-02-07 Utilisation de chitosane pour augmenter le taux de croissance des ongles

Publications (1)

Publication Number Publication Date
MA31236B1 true MA31236B1 (fr) 2010-03-01

Family

ID=38345983

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32200A MA31236B1 (fr) 2007-02-14 2009-09-04 Utilisation de chitosane pour augmenter le taux de croissance des ongles

Country Status (31)

Country Link
US (3) US8680074B2 (fr)
EP (3) EP1958638A1 (fr)
JP (3) JP5426401B2 (fr)
KR (2) KR101323762B1 (fr)
CN (2) CN102988405A (fr)
AR (1) AR065316A1 (fr)
AT (1) ATE522221T1 (fr)
AU (1) AU2008214693B2 (fr)
BR (1) BRPI0807595A2 (fr)
CA (1) CA2677715C (fr)
CL (2) CL2008000444A1 (fr)
CO (1) CO6230979A2 (fr)
CY (2) CY1112058T1 (fr)
DK (2) DK2377541T3 (fr)
EA (2) EA201270116A1 (fr)
ES (2) ES2436647T3 (fr)
HR (2) HRP20110667T1 (fr)
IL (1) IL200269A (fr)
MA (1) MA31236B1 (fr)
ME (1) ME00830B (fr)
MX (1) MX2009008686A (fr)
MY (2) MY154499A (fr)
NZ (1) NZ578896A (fr)
PH (1) PH12014500274A1 (fr)
PL (2) PL2117564T3 (fr)
PT (2) PT2117564E (fr)
RS (2) RS53143B (fr)
SI (2) SI2377541T1 (fr)
UA (1) UA100011C2 (fr)
WO (1) WO2008098869A2 (fr)
ZA (1) ZA200905443B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
WO2010109423A1 (fr) * 2009-03-25 2010-09-30 Sulur Subramaniam Vanangamudi Crème médicinale antifongique à base de stéroïdes et comprenant du chitosane, et son procédé de fabrication
CN103987370A (zh) * 2011-10-05 2014-08-13 阿勒根公司 用于增进指甲健康的组合物
WO2013093216A1 (fr) * 2011-12-20 2013-06-27 Laboratoires Urgo Composition topique filmogène et son utilisation pour traiter ou prévenir l'onychophagie
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP2845597A1 (fr) * 2013-09-10 2015-03-11 Polichem S.A. Hydroxypropylchitosan pour le traitement de l'onychomycose
EP2910245A1 (fr) * 2014-02-21 2015-08-26 Polichem SA Composition antifongique topique pour le traitement de l'onychomycose
CN109893472A (zh) * 2019-04-09 2019-06-18 涿州皓原箔业有限公司 一种环保无毒水性卸甲液及其制备方法
ES2834732B2 (es) * 2019-12-17 2022-03-24 Univ Valladolid Solucion acuosa que comprende un complejo de inclusion, metodo de obtencion y su uso para aplicacion en cultivos y la mejora de su rendimiento
CN111388416B (zh) * 2020-02-26 2022-03-08 浙江康德药业集团股份有限公司 一种盐酸利多卡因胶浆剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541305A1 (de) 1985-11-22 1987-05-27 Wella Ag Kosmetische mittel auf der basis von n-hydroxypropylchitosanen, neue n-hydroxypropyl-chitosane sowie verfahren zu ihrer herstellung
DE3723811A1 (de) * 1987-07-18 1989-01-26 Wella Ag Nagellack auf der basis von o-benzyl-n-hydroxyalkylchitosanen sowie neue o-benzyl-n-hydroxyalkylderivate des chitosans
CA2008775C (fr) 1989-02-24 1998-12-22 Alberto Ferro Vernis a ongles
ES2101263T3 (es) 1993-02-19 1997-07-01 Howard Green Composiciones que contienen proteinas de corneocitos.
FR2718637A1 (fr) * 1994-04-15 1995-10-20 Oreal Composition cosmétique à appliquer sur l'ongle.
RU2108114C1 (ru) * 1996-12-27 1998-04-10 Товарищество с ограниченной ответственностью Научно-производственное предприятие "Эрлон", Лтд. Биологическая композиция для лечения ран "коллахит"
ITTO980264A1 (it) 1998-03-26 1999-09-26 Silvio Rossi Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica
US6391334B1 (en) * 1999-10-25 2002-05-21 Amway Corporation Barrier-forming composition
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
SI1455802T1 (sl) * 2001-12-14 2009-06-30 Dnp Canada Inc Uporaba hitozanskih oligosaharidov
EP1440683A1 (fr) * 2003-01-23 2004-07-28 Cognis France S.A. Utilisation des oligoglucosamines dans des compositions cosmétiques ou dermatologiques
EP1491202A1 (fr) 2003-06-23 2004-12-29 Polichem S.A. Compositions pour l'application à la surface d'ongles pour les réstructurer
JP3881992B2 (ja) 2004-07-30 2007-02-14 シャープ株式会社 受信装置、受信プログラム、および受信プログラムを記録した記録媒体
WO2006111426A1 (fr) * 2005-04-19 2006-10-26 Galderma S.A. Composition d'une solution de type filmogene, comprenant de la vitamine d ou un de ses derives et un corticosteroide, et son utilisation en dermatologie
FR2892023B1 (fr) * 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102006049585A1 (de) * 2006-10-22 2008-04-24 Susilo, Rudy, Dr. Nagellack für kosmetische und medizinische Anwendungen

Also Published As

Publication number Publication date
CN101663039B (zh) 2013-08-07
WO2008098869A2 (fr) 2008-08-21
JP2015221823A (ja) 2015-12-10
JP6045663B2 (ja) 2016-12-14
WO2008098869A3 (fr) 2008-10-09
JP5426401B2 (ja) 2014-02-26
PT2117564E (pt) 2011-10-17
KR101131015B1 (ko) 2012-03-29
MY163297A (en) 2017-09-15
EP1958638A1 (fr) 2008-08-20
JP2010518138A (ja) 2010-05-27
US20100152133A1 (en) 2010-06-17
IL200269A (en) 2015-10-29
EA018390B1 (ru) 2013-07-30
EP2377541A1 (fr) 2011-10-19
NZ578896A (en) 2012-02-24
CA2677715A1 (fr) 2008-08-21
ES2369116T3 (es) 2011-11-25
PL2117564T3 (pl) 2012-03-30
ATE522221T1 (de) 2011-09-15
AU2008214693A2 (en) 2009-09-10
RS53143B (sr) 2014-06-30
AU2008214693B2 (en) 2013-05-02
PT2377541E (pt) 2013-11-21
SI2377541T1 (sl) 2014-01-31
KR20110075043A (ko) 2011-07-05
ES2436647T3 (es) 2014-01-03
CN102988405A (zh) 2013-03-27
CO6230979A2 (es) 2010-12-20
AU2008214693A1 (en) 2008-08-21
CA2677715C (fr) 2014-10-14
US20140147401A1 (en) 2014-05-29
SI2117564T1 (sl) 2011-12-30
CN101663039A (zh) 2010-03-03
US20160015620A1 (en) 2016-01-21
DK2117564T3 (da) 2011-10-17
CL2013002052A1 (es) 2014-02-21
US8680074B2 (en) 2014-03-25
AR065316A1 (es) 2009-05-27
HRP20131175T1 (hr) 2014-01-17
US9173827B2 (en) 2015-11-03
CL2008000444A1 (es) 2008-08-22
EP2377541B1 (fr) 2013-10-23
JP2013213048A (ja) 2013-10-17
KR101323762B1 (ko) 2013-11-01
IL200269A0 (en) 2010-04-29
MX2009008686A (es) 2009-08-21
HRP20110667T1 (hr) 2011-10-31
ZA200905443B (en) 2010-10-27
PH12014500274A1 (en) 2016-06-06
DK2377541T3 (da) 2013-11-11
RS52031B (sr) 2012-04-30
CY1115136T1 (el) 2016-12-14
PL2377541T3 (pl) 2014-04-30
EP2117564B1 (fr) 2011-08-31
MY154499A (en) 2015-06-30
ME00830B (fr) 2012-03-20
HK1133189A1 (en) 2010-03-19
UA100011C2 (ru) 2012-11-12
KR20090121312A (ko) 2009-11-25
BRPI0807595A2 (pt) 2014-07-22
EA200901093A1 (ru) 2010-02-26
EP2117564A2 (fr) 2009-11-18
EA201270116A1 (ru) 2012-06-29
CY1112058T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
WO2010115843A3 (fr) Composition pharmaceutique
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
PH12015502017A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune disease
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
NO20092651L (no) Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
WO2009149486A3 (fr) Composés destinés au traitement de maladies
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
PH12014500274A1 (en) Use of chitosans to increase nail growth rate
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
NO20084396L (no) Kombinasjonsterapi
GEP20166454B (en) Sclerostin binding agents
CL2013001471A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
EP2438962A3 (fr) Polynucléotides et séquences de polypeptides impliqués dans le procédé de remodelage des os
WO2011031493A3 (fr) Galectine-3 et thérapie de resynchronisation cardiaque
WO2010007031A3 (fr) Procédés pour améliorer la différenciation cardiaque des cellules souches embryonnaires humaines
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
WO2010042489A3 (fr) Inhibiteurs de la protéine de choc thermique 90 dérivés d'aminoquinoline, leurs procédés de préparation et leurs procédés d'utilisation
EP2199306A3 (fr) Anticorps humain spécifique VEGF
EP2741768A4 (fr) Compositions, procédés et utilisations d'alpha 1-antitrypsine pour une intervention précoce dans la transplantation de la moelle osseuse et traitement d'une maladie de greffon contre l'hôte
WO2009090650A3 (fr) Vaccin contre la maladie d'alzheimer
WO2008063746A8 (fr) Méthode de traitement de la maladie intestinale inflammatoire
WO2010115034A3 (fr) Biomarqueurs protéiques utilisables pour le diagnostic de maladies affectant les tissus mous et en tant que cibles thérapeutiques lors de soins bucco-dentaires
WO2006113790A3 (fr) Compositions et procedes pour le traitement du cancer
WO2006003492A3 (fr) Compositions et methodes de traitement d'infections pathologiques